Nat Rev Drug Discov. 2002 Apr;1(4):309-15.

Protein kinases--the major drug targets of the twenty-first century?

Source

Medical Research Council, Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK. p.cohen@dundee.ac.uk

Abstract

Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease. A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clinical use. Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors. Here, I give a personal view of some of the most important advances that have shaped this field.

PMID:: 12120282; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

ClinicalTrials.gov

Molecular Biology Databases

IMATINIB MESYLATE - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review Protein kinase inhibitors as a therapeutic modality. [Acc Chem Res. 2003]
Review Protein kinase inhibitors as a therapeutic modality.
Levitzki A. Acc Chem Res. 2003 Jun; 36(6):462-9.
Review The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. [Curr Med Chem. 2004]
Review The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases.
Fischer PM. Curr Med Chem. 2004 Jun; 11(12):1563-83.
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. [Cancer Res. 2002]
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S. Cancer Res. 2002 Jan 1; 62(1):188-99.
Review Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. [Drugs. 2003]
Review Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF, Perry CM. Drugs. 2003; 63(5):513-22; discussion 523-4.
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. [Cancer Chemother Pharmacol. 2003]
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA, Laug WE, Sausville EA, Avramis VI. Cancer Chemother Pharmacol. 2003 Oct; 52(4):307-18. Epub 2003 Jun 25.

See reviews... See all...

Cited by over 100 PubMed Central articles

Using existing drugs as leads for broad spectrum anthelmintics targeting protein kinases. [PLoS Pathog. 2013]
Using existing drugs as leads for broad spectrum anthelmintics targeting protein kinases.
Taylor CM, Martin J, Rao RU, Powell K, Abubucker S, Mitreva M. PLoS Pathog. 2013 Feb; 9(2):e1003149. Epub 2013 Feb 14.
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors. [PLoS One. 2013]
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Balabanov S, Wilhelm T, Venz S, Keller G, Scharf C, Pospisil H, Braig M, Barett C, Bokemeyer C, Walther R, et al. PLoS One. 2013; 8(1):e53668. Epub 2013 Jan 9.
Roles of Polo-like kinase 3 in suppressing tumor angiogenesis. [Exp Hematol Oncol. 2012]
Roles of Polo-like kinase 3 in suppressing tumor angiogenesis.
Xu D, Wang Q, Jiang Y, Zhang Y, Vega-Saenzdemiera E, Osman I, Dai W. Exp Hematol Oncol. 2012 Apr 18; 1(1):5. Epub 2012 Apr 18.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Protein kinases--the major drug targets of the twenty-first century?
Protein kinases--the major drug targets of the twenty-first century?
Nat Rev Drug Discov. 2002 Apr ;1(4):309-15.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Protein kinases--the major drug targets of the twenty-first century?

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by over 100 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information